Skip to content

Psyllium Fiber Versus Placebo in Early Treatment After STARR for Obstructed Defecation: a Double-blind RCT

Efficacia Della Fibra di Psyllium Versus Placebo Nella Gestione Dell'Alvo in Pazienti Sottoposti ad Intervento Chirurgico Per Ostruita Defecazione

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02136693
Enrollment
65
Registered
2014-05-13
Start date
2010-05-31
Completion date
2011-12-31
Last updated
2014-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Constipation, Incontinence

Keywords

obstructed defecation, STARR, constipation, incontinence, psyllium

Brief summary

This study aims to assess whether fiber intake, formerly recommended only before or instead of surgery, may play a role in improving postoperative progress and functional outcome after STARR for obstructed defecation, in terms of residual constipation, incontinence and defecation urgency.

Detailed description

After obtaining written informed consent and collecting baseline scores (T0), each patient was randomly assigned to one of the two groups and began taking sachets containing Psyllium fiber 3.5 g / day for Active group (A) and inert compound for Placebo group (P). Sachet content was assigned by software randomization, written on a list and sealed in an envelope, which was opened only after the study was completed. Post-operative instructions for both groups included only analgesic therapy (Ketorolac 10 to 30 mg b.m. if needed). Patients were also asked to stop any former laxative and to continue on a normal diet. Each patient was re-evaluated at 7 ± 3 (T1), 60 ± 5 (T2) and 180 ± 15 (T3) days after surgery (Table 2). A fluoroscopic colpocystodefecography (with patient sitting upright) was obtained before surgery and between 60-180 days postoperatively in order to assess comparability of the two groups and exclude negative organic outcomes that could affect functional results. Medical events were investigated while checking each patient, with special regard to defecation urgency. From the data collected on concomitant medications, we extrapolated those related to laxative intake. The treatment was considered accomplished in patients who had taken at least 70% of the product during each interval of follow-up. Statistical analysis was performed using the SPSS - PASW Statistics 18.0.0 (IBM ©, 2009). For the general and defecographic characteristics, the data are expressed in the form of mean ± standard deviation for continuous variables and absolute frequency (frequency percentages) for categorical variables. The differences between the two groups were calculated by two-tailed t-test or chi-square when appropriate. Scores for the assessment of clinical data are expressed as mean ± standard deviation and analysis of the differences in the two groups was performed using the two-tailed t-test. The analysis of not normally distributed variables was conducted using a non-parametric test (Wilcoxon-Mann-Whitney). Analyses related to defecation urgency and use of laxatives were carried out using chi-square test and the data are expressed as absolute frequency (frequency percentage). For all tests, a value of p \<0.05 was considered significant.

Interventions

DRUGPsyllium fiber

3.5 g /day of pure Psyllium fiber for 180 days after STARR

DRUGPlacebo

3.5 g /day of inert compound for 180 days after STARR

Sponsors

Francesco Gabrielli
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Written informed consent * Age over 18 * Diagnosis of Obstructed Defecation Syndrome according to ODS and CCS Score * STARR performed when ODS score \>10 * STARR performed 48-72 hours before

Exclusion criteria

* Puborectalis or sphincter dyssynergia, evaluated by defecography and / or anorectal manometry * Concomitant diseases (fissure, abscess, fistula, IBD, diverticular disease) * Prolapse of other pelvic floor organs * Proctological surgery before STARR * Pregnancy or breast-feeding * Ongoing treatment with oral anticoagulants or steroid therapy * Conditions that do not allow patients to understand the nature and the purpose of the study

Design outcomes

Primary

MeasureTime frameDescription
residual constipation180 days after STARRODS score and CCS score

Secondary

MeasureTime frameDescription
Post-operative pain180 days after STARRVAS
revertence to laxative use180 days after STARRfrequency percentage of patients that reverted to laxative use after surgery
change in fecal incontinence from baseline180 days after STARRWexner Incontinence score
post-operative defecation urgency180 days after STARRdefecation urgency incidence

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026